Difficulty: Medium
Average Score: 74%
Practice
A patient with focal complex partial seizures has been treated for 6 months with carbamazepine but, recently, has been experiencing breakthrough seizures on a more frequent basis. You are considering adding a second drug to the antiseizure regimen. Which of the following drugs is least likely to have a pharmacokinetic interaction with carbamazepine?
Correct answer
C
Rationale
Carbamazepine induces cytochrome P450 (e.g., CYP3A4), accelerating metabolism of drugs like topiramate, tiagabine, and lamotrigine, reducing their levels and complicating dosing. Levetiracetam, excreted renally with minimal hepatic metabolism, avoids P450 interactions, maintaining stable levels when added to carbamazepine. Zonisamide interacts via induction. Levetiracetam's lack of pharmacokinetic interference, per clinical pharmacology, makes it the safest adjunct, enhancing control without altering carbamazepine's efficacy.